Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lomitapide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP known ✓ | P55157 | 15/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | MTR | Q99707 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lomitapide SCHEMBL29355521 | 1.00 | MTTP (1.00) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| Lomitapide SCHEMBL2731380 | 0.96 | MTTP (1.00) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| Lomitapide SCHEMBL29367678 | 0.96 | MTTP (1.00) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL16519940 | 0.94 | MTTP (0.88) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL19509698 | 0.94 | MTTP (0.88) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL6600443 | 0.93 | MTTP (0.86) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL6188141 | 0.92 | MTTP (0.85) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL6603726 | 0.92 | MTTP (0.85) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL10332067 | 0.92 | MTTP (0.85) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL19500371 | 0.92 | MTTP (0.85) | MTTPCHRM2ADRA2AADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 781 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381166-A1 | METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2023-11-30 | — | — | US | claimed |
| US-20230109871-A1 | METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2023-04-13 | — | — | US | claimed |
| US-10555938-B2 | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2020-02-11 | — | — | US | claimed |
| US-20180318278-A1 | Methods for Treating Disorders or Diseases Associated with Hyperlipidemia and Hypercholesterolemia While Minimizing Side Effects | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2018-11-08 | — | — | US | claimed |
| US-10016404-B2 | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-07-10 | — | — | US | claimed |
| US-20170258776-A1 | Methods for Treating Disorders or Diseases Associated with Hyperlipidemia and Hypercholesterolemia While Minimizing Side Effects | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2017-09-14 | — | — | US | claimed |
| WO-2017098522-A1 | CRYSTALLINE POLYMORPH OF N-(2,2,2-TRIFLUOROETHYL-9-[4-[R4-R[[[I4'- (TRIFLUOROMETHYL) [ 1,1 ' -BIPHENYL] -2-YL] CARBONYL] AMINO] -1 -PIPERIDINYL] BUTYL] -9H- FLUORENE-9-CARBOXAMIDE METHANESULFONATE AND PROCESS FOR PREPARATION THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2017-06-15 | — | — | WO | claimed |
| US-20160331739-A1 | METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE-EFFECTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2016-11-17 | — | — | US | claimed |
| US-20160256446-A1 | METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE-EFFECTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2016-09-08 | — | — | US | claimed |
| US-9433617-B1 | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-09-06 | — | — | US | claimed |
| US-20110288064-A1 | METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL | AEGERION PHARMACEUTICALS, INC. | 2011-11-24 | — | — | US | claimed |
| US-20090054393-A1 | METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL | AEGERION PHARMACEUTICALS, INC. | 2009-02-26 | — | — | US | claimed |
| EP-1806149-A1 | SOLID MEDICINAL PREPARATION IMPROVED IN SOLUBILITY AND STABILITY AND PROCESS FOR PRODUCING THE SAME | Japan Tobacco, Inc. (JP) | 2007-07-11 | — | — | EP | claimed |
| US-20060153913-A1 | Solid formulation with improved solubility and stability, and method for producing said formulation | JAPAN TOBACCO INC. (JP) | 2006-07-13 | — | — | US | claimed |
| EP-1465613-A2 | COMBINATION OF MTP INHIBITORS OR APOB SECRETION INHIBITORS WITH FIBRATES FOR USE AS DRUGS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2004-10-13 | — | — | EP | claimed |
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-08-28 | — | — | US | claimed |
| WO-2003057205-A2 | COMBINATION OF MTP INHIBITORS OR APOB SECRETION INHIBITORS WITH FIBRATES FOR USE AS DRUGS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-07-17 | — | — | WO | claimed |
| EP-1099438-A2 | Use of APO B secretion/MTP inhibitors | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| EP-1099439-A2 | Use of apo B secretion/MTP inhibitors | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| EP-1099441-A2 | Compositions containing apo B secretion/MTP inhibitors and anti-obesity agents and use thereof | Pfizer Products Inc. (US) | 2001-05-16 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10555938-B2 | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects | APOB, CETP, MTTP | MTTP 3/4885CHRM2 4317/4885ADRA2A 3034/4885 |
| US-20160331739-A1 | METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE-EFFECTS | APOB, CETP, MTTP | MTTP 3/4885CHRM2 4547/4885ADRA2A 3547/4885 |
| US-20230109871-A1 | METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS | APOB, CETP, MTTP | MTTP 3/4885CHRM2 4317/4885ADRA2A 3034/4885 |
| US-20160256446-A1 | METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE-EFFECTS | APOB, CETP, MTTP | MTTP 3/4885CHRM2 4547/4885ADRA2A 3547/4885 |
| US-20030162788-A1 | Combination of MTP inhibitors or apoB-secretion inhibitors with fibrates for use as pharmaceuticals | APOB, LIPC, MTPN | MTTP 9/4885CHRM2 4457/4885ADRA2A 1810/4885 |
| US-20170258776-A1 | Methods for Treating Disorders or Diseases Associated with Hyperlipidemia and Hypercholesterolemia While Minimizing Side Effects | APOB, CETP, MTTP | MTTP 3/4885CHRM2 4317/4885ADRA2A 3034/4885 |
| US-20180318278-A1 | Methods for Treating Disorders or Diseases Associated with Hyperlipidemia and Hypercholesterolemia While Minimizing Side Effects | APOB, CETP, MTTP | MTTP 3/4885CHRM2 4317/4885ADRA2A 3034/4885 |
| US-20090054393-A1 | METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL | CETP, APOB, MTTP | MTTP 3/4885CHRM2 4846/4885ADRA2A 4197/4885 |
| US-10016404-B2 | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects | APOB, CETP, MTTP | MTTP 3/4885CHRM2 4317/4885ADRA2A 3034/4885 |
| US-20230381166-A1 | METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTS | APOB, CETP, MTTP | MTTP 3/4885CHRM2 4317/4885ADRA2A 3034/4885 |
| US-20060153913-A1 | Solid formulation with improved solubility and stability, and method for producing said formulation | ABCG2, SORD, SRI | MTTP 1276/4885CHRM2 1209/4885ADRA2A 3959/4885 |
| US-20110288064-A1 | METHODS FOR TREATING DISORDERS ASSOCIATED WITH HYPERLIPIDEMIA IN A MAMMAL | CETP, APOB, MTTP | MTTP 3/4885CHRM2 4846/4885ADRA2A 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.